Literature DB >> 10394995

Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils.

M Poncelet1, M C Barnouin, J C Brelière, G Le Fur, P Soubrié.   

Abstract

RATIONALE: A cannabinoid hypothesis of schizophrenia has been proposed according to which cognitive dysfunction could be associated with dysregulation of an endogenous cannabinoid system.
OBJECTIVE: The present study investigated whether SR 141716, a selective CB1 receptor antagonist, was able to reduce the hyperactivity induced in gerbils by various stimulant drugs known to produce or exacerbate schizophrenic symptoms.
METHODS: Cocaine, d-amphetamine, morphine, and Win 55212-2 were administered intraperitoneally (IP) either immediately before placing the animals in the test apparatus (non-habituated gerbils) or after a 2- to 3-h habituation period in the actimeter (habituated gerbils). SR 141716 was given IP 30 min before the injection of stimulant drugs. Horizontal activity was recorded every 10 min for 1 h in Digiscan activity monitor.
RESULTS: SR 141716 (0.3-3 mg/kg) dose-dependently suppressed the enhanced locomotor activity induced by each stimulant drug in habituated gerbils, but not in non-habituated animals. Clozapine, an atypical antipsychotic compound, but not haloperidol, shared with SR 141716, the ability to differentially affect drug-induced hyperactivity in habituated versus non-habituated gerbils.
CONCLUSION: The activation of cannabinoid systems is a required, permissive element in the ability of cocaine, d-amphetamine, morphine, and Win 55212-2 to reinstate behaviour, i.e., to override stimulus satiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10394995     DOI: 10.1007/s002130050987

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  10 in total

1.  The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Authors:  Eleni T Tzavara; Richard J Davis; Kenneth W Perry; Xia Li; Craig Salhoff; Frank P Bymaster; Jeffrey M Witkin; George G Nomikos
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

2.  AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors:  Mark D Black; Rachel J Stevens; Nancy Rogacki; Robert E Featherstone; Yaw Senyah; Odessa Giardino; Beth Borowsky; Jeanne Stemmelin; Caroline Cohen; Philippe Pichat; Michal Arad; Segev Barak; Amaya De Levie; Ina Weiner; Guy Griebel; Geoffrey B Varty
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

Review 3.  Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention.

Authors:  F Markus Leweke; Juliane K Mueller; Bettina Lange; Stefan Fritze; Cristina E Topor; Dagmar Koethe; Cathrin Rohleder
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

Review 4.  Cannabis-associated psychosis: current status of research.

Authors:  F Markus Leweke; Christoph W Gerth; Joachim Klosterkötter
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Methanandamide attenuates cocaine-induced hyperthermia in rats by a cannabinoid CB1-dopamine D2 receptor mechanism.

Authors:  Bruce A Rasmussen; Esther Kim; Ellen M Unterwald; Scott M Rawls
Journal:  Brain Res       Date:  2009-01-18       Impact factor: 3.252

Review 6.  Modulation of the endocannabinoid system: therapeutic potential against cocaine dependence.

Authors:  Gianluigi Tanda
Journal:  Pharmacol Res       Date:  2007-09-11       Impact factor: 7.658

Review 7.  Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia.

Authors:  Marc Fakhoury
Journal:  Mol Neurobiol       Date:  2016-01-15       Impact factor: 5.590

8.  Opposing roles of CB1 and CB2 cannabinoid receptors in the stimulant and rewarding effects of cocaine.

Authors:  Pedro H Gobira; Ana C Oliveira; Julia S Gomes; Vivian T da Silveira; Laila Asth; Juliana R Bastos; Edleusa M Batista; Ana C Issy; Bright N Okine; Antonio C de Oliveira; Fabiola M Ribeiro; Elaine A Del Bel; Daniele C Aguiar; David P Finn; Fabricio A Moreira
Journal:  Br J Pharmacol       Date:  2018-09-14       Impact factor: 8.739

9.  Behavioral and electrophysiological effects of endocannabinoid and dopaminergic systems on salient stimuli.

Authors:  Daniela Laricchiuta; Alessandra Musella; Silvia Rossi; Diego Centonze
Journal:  Front Behav Neurosci       Date:  2014-05-19       Impact factor: 3.558

Review 10.  Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction.

Authors:  Stéphanie Olière; Antoine Joliette-Riopel; Stéphane Potvin; Didier Jutras-Aswad
Journal:  Front Psychiatry       Date:  2013-09-23       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.